A Better Way Forward for Late Stage and Complex Cancers
Share this page:
After decades of research from some of the top cancer institutions in the world, immunotherapies are finally moving to the forefront to help patients with late stage and complex cancers. Unfortunately, these cancer treatments are not traditionally available to cancer patients. Treatments such as oncolytic viruses, genetically modified dendritic cell therapy, natural killer cell therapy, T-cell therapy, and checkpoint inhibitors are all becoming the primary focus of cancer documentaries and will become standard treatment over the next decade in oncology, but access to these highly effective treatments is hard to come by. Fortunately, international integrative cancer centers like Envita Medical Center are utilizing these immunotherapy technologies now.
Envita Medical Centers doesn't make any guarantee of outcomes. Results are not typical and will vary from person to person and should not be expected.
The validation for these treatments has been in the published studies for some time. In 2013, a medical study using T-cells and natural killer cells offered life extending/saving responses for cancer patients who had failed other treatments like chemotherapy. The life extending/saving responses included those suffering from late-stage cancers. Another study, also in 2013, using CD-19 directed chimeric antigen receptors (CAR)-expressing T-cells (natural killer cells) showed dramatic results in the treatment of acute lymphoblastic leukemia as well as B-cell Lymphoma. The complete remission rates reported were as high as 90% with children and adults with relapsed B-cell Lymphoma [1]. In 2015, T-vec, the first United States approved oncolytic virus, became available for the treatment of melanoma. T-vec is a non-pathogenic virus, meaning it only infects and destroys cancer cells without harming normal healthy tissues [2]. Multiple cancer types beyond melanoma and being studied against T-vec’s effectiveness in combination with smart immunotherapy drugs [3]. T-vec is only the tip of the iceberg as many new oncolytic viruses are in the pipeline. With these advanced immunotherapies, the patient’s real-time cancer cell mutations determine the customized treatments.
Over the last 10 years, the doctors at Envita have been developing highly personalized targeted options for patients that have failed every major cancer hospital in the country. Envita has published several peer reviewed studies on the subject that has paved the way to developing their customized immunotherapy treatment called IMX. IMX, or immune modulation treatment, utilizes an exclusive technology and approach to activating the immune system to help fight cancer. Envita’s scientific research paper, “Immunotherapy in Cancer Treatment,” published in the Open Journal of Medical Microbiology, focuses on the most significant types of immunotherapies currently available around the world. The research paper, “Autologous Natural Killer Cell/Natural Killer T Cell Immunotherapy of Malignant Diseases,” focuses on a specific type of immunotherapy called autologous immunotherapy. This type of immunotherapy plays a huge part in IMX treatment. With IMX, natural killer cells are removed from the patient and multiplied before being reintroduced back into the body. These trained natural killer cells find and attack the patient’s cancer target and is what makes all the difference in effective immunotherapy treatment in our clinical opinion. The components offered in IMX are not all FDA approved for cancer treatment in the United States however; Envita believes that treatment combinations like IMX will be the future of cancer treatment.
The diagram below explains an overview of IMX Treatment
In our opinion, combination-immunotherapies such as IMX allow for a high level of personalization in cancer treatment in order for patients to experience the maximum potential benefits. For any questions or concerns about immunotherapy and IMX or anything else in this article, feel free to contact Envita.
Disclaimer: Some of the treatments mentioned (like IMX) in the above article are not all available in the US and are not FDA approved for the treatment or diagnosis of cancer. Patients should consult with their doctors before undergoing treatment or altering medical care. Envita Mexico is under Mexican law and jurisdiction and in no way does Envita make guarantees or claims of any outcomes for this or any treatment. In cancer treatment, individual results will vary and outcomes should not be expected. The information above is for education purposes only. Not all patient are candidates for IMX or immunotherapies and should consult their doctors.
References
Castellino, Alexander M and Zosia Chustecka. “Immunotherapy: Backbone of Future Lung Cancer Treatment?” Medscape. 18 June 2015. http://www.medscape.com/viewarticle/846679.
Smith Aaron, Oertle John, Prato Dino, Immunotherapy in Cancer Treatment Open Journal of Medical Microbiology Vol.4 No.3, September 2014 http://www.scirp.org/journal/PaperInformation.aspx?PaperID=49598
Smith Aaron, Oertle John, Prato Dino, Autologous Natural Killer Cell/Natural Killer T Cell Immunotherapy of Malignant Diseases Open Journal of Medical Microbiology Vol.4 No.3, September 2014 http://www.scirp.org/journal/PaperInformation.aspx?PaperID=49600
Research
1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368:1509-18.
2. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015; 14:642-62
3. J Clin Oncol 32:5s, 2014 (suppl; abstr 9029^)
To better understand our unique approach to cancer treatment:
Envita Medical Center Continues to Be Fully Operational During the COVID-19 Outbreak
We at Envita Medical Center do not have the typical corporate response to the COVID-19 pandemic. For the last 20 years, we have been leaders in the field of advanced integrative medicine and immunotherapy. We are not simply taking precautions but providing prophylactic support for our patients' immune systems against viral and bacterial infections. Our aim is to keep our patients and staff in optimal health with stronger immune systems.
With the country issuing stay-at-home orders, cancer patients with late-stage diagnoses do not have the luxury to wait weeks or months for this pandemic to pass before seeking treatment. Cancer is an ever-changing disease that needs immediate and targeted treatment options to prevent further advancement and complications. Having the appropriate immunotherapy options available to our patients makes all the difference with how the lungs and body respond to infection, especially aggressive respiratory viruses.
At Envita Medical Center, your health, immunity, safety, and healing are the highest priority to us. We are not a community hospital; patients are carefully screened and receive treatment from us for weeks or months at a time (maintaining the same community). We want to assure you that our team of physicians and nurses are up to date with the most current COVID-19 research and data. In fact, we have been asked to share our strategies with members of The White House and major hospitals around the country to provide immunotherapy protocols to aid in the prevention and treatment of COVID-19 for patients and first responders.
Please review the protective measures Envita has put in place to protect our patients and staff:
We are actively and prophylactically treating our patients and staff with antiviral immune protective measures to maintain strong immune systems and reduce the risk of infection.
We are actively monitoring where incoming patients and caregivers have traveled in the past 60 days and if they have been experiencing any symptoms. However, due to the many asymptomatic carriers, we treat all our patients as though they have weak immunity and are at risk for infections.
We have put in place a telemedicine platform for our patients to be assessed and tested before coming to Envita to receive treatment.
All active patients and deemed medically necessary caregivers are provided protective N95 masks to wear throughout the treatment area and center.
We have an array of treatments that are designed to fight infection, support the immune system, and promote respiratory health that are being used prophylactically.
The Envita team is providing routine cleans with peroxide wipes and CaviWipes before and after each patient throughout the day with protective masking and gloves.
Our hospital certified cleaning crew performs nightly cleaning with medical grade products and disinfectants.
All Envita team is wearing protective N95 masks as an added layer of protection.
We have a top-of-the-line HEPA air purification system with nightly ozone purification and multiple HEPA filters throughout the entire facility.
We have moved all non-essential personnel form our corporate offices to work-from-home, however, our pharmacy team continues to supply medications to thousands of doctors across the country who are treating and helping with COVID-19.
We have procured medication and supplies for many months to ensure our team does not run short on any medication, supplies, or immunotherapies.
When being faced with challenges like these, it is important to realize that Envita Medical Center is one of the safest places you can be during this pandemic because we are taking all the necessary precautions to ensure our patients continue to receive the lifesaving treatments they need to help aid in overcoming late-stage cancer and complex infectious diseases like debilitating Lyme disease. We are here for you, our patients, and may God bless you on your journey to healing. If you have any questions, please do not hesitate to reach out to Envita Medical Center at 866-830-4576, we have trained professionals standing by to help guide you on the path toward healing.
Envita Medical Center continues to be fully operational during the COVID-19 outbreak
